Facile Entry into Triazole Fused Heterocycles via Sulfamidate Derived Azido-alkynes
作者:V. Sai Sudhir、N. Y. Phani Kumar、R. B Nasir Baig、Srinivasan Chandrasekaran
DOI:10.1021/jo9016748
日期:2009.10.2
Direct synthesis of condensed triazoles from diverse sulfamidates by ring opening of sulfamidates with sodium azide followed by one-pot propargylation and cycloaddition furnished title compounds. The methodology in general has been demonstrated on diverse sulfamidates derived from amino acids, amino acid derivatives, and carbohydrates to obtain diverse triazole fused scaffolds. In one example, a condensed
copper(I)‐catalyzed azide‐alkyne cycloaddition (CuAAC) of cyclicsulfates or cyclic sulfamidates in the presence of sodium azides and alkynes is reported. The developed protocol takes also advantage of the concomitant use of microwave (MW) irradiation and heterogeneous catalysis. The protocol allows the fast and efficient preparation of (alkyl sulfate)‐ and (alkyl sulfamidate)‐1H‐1,2,3‐triazoles in a simple
报道了一种在叠氮化钠和炔烃存在的情况下涉及串联叠氮化和单击铜(I)催化的环状硫酸盐或环状氨基磺酸盐的叠氮化物-炔烃环加成(CuAAC)的单锅,三组分方法。所开发的协议还利用了微波(MW)辐照和非均相催化的同时使用。该方案允许以简单的方式快速有效地制备(烷基硫酸盐)-和(氨基磺酸烷基酯)-1 H -1,2,3-三唑。
Lanthionine Peptides by <i>S</i>-Alkylation with Substituted Cyclic Sulfamidates Promoted by Activated Molecular Sieves: Effects of the Sulfamidate Structure on the Yield
作者:Stefania De Luca、Giuseppe Digilio、Valentina Verdoliva、Pablo Tovillas、Gonzalo Jiménez-Osés、Jesús M. Peregrina
DOI:10.1021/acs.joc.9b02306
日期:2019.11.15
for preparing lanthionine peptides by a highly chemoselective and stereochemically controlled procedure is presented. It involves an S-alkylation reaction, promoted by activated molecular sieves, on chiral cyclic sulfamidates, both N-protected and unprotected. Of note, the reaction yield was high also for cyclic sulfamidates bearing a free amine group, while other strategies failed to achieve a ring-opening
[EN] CYCLIC COMPOUNDS AND METHODS OF USING SAME<br/>[FR] COMPOSÉS CYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
申请人:SCHROEDINGER INC
公开号:WO2021113492A1
公开(公告)日:2021-06-10
The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for inhibiting kinase activity, and for treating cancer.